Evidence map›Paper›PMID 34656107›Full record

ArticleBMC cancer2021

Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.

Mototsugu Shimokawa, Toshinobu Hayashi, Junichi Nishimura, Taroh Satoh, Mutsumi Fukunaga, Reiko Matsui, Yasushi Tsuji, Fumitaka Mizuki, Takahiro Kogawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 1 country.

Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan. moto@yamaguchi-u.ac.jp.
Toshinobu HayashiDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Taroh SatohDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, Japan.
Mutsumi FukunagaDepartment of surgery, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
Reiko MatsuiDepartment of Pharmacy, National Cancer Center Hospital EastChiba, Kashiwa, Japan.
Yasushi TsujiDepartment of Medical Oncology, Tonan Hospital, Sapporo, Hokkaido, Japan.
Fumitaka MizukiCenter For Clinical Research, Yamaguchi University Hospital, Yamaguchi, Japan.
Takahiro KogawaDivision of Early Clinical Development for Cancer, Advanced Medical Development Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Fukuoka University · JPHyogo Prefectural Nishinomiya Hospital · JPJapanese Foundation For Cancer Research · JPNational Cancer Center Hospital East · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPOsaka University · JPTonan Hospital · JPYamaguchi University · JPYamaguchi University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled.

methodsWe pooled data from two prospective observational studies in Japan and one phase III clinical trial to assess whether delayed CINV could be controlled with a combination of three antiemetics adding a neurokinin-1 receptor antagonist and identified individual risk factors, using an inverse probability treatment-weighted analysis.

resultsA total of 661 patients were evaluable in this study (median age: 64 years; 391 male, and 270 female). 3 antiemetics controlled delayed nausea (33.18% vs. 42.25%; p = 0.0510) and vomiting (4.15% vs. 16.08%; p < 0.0001) better than with 2 antiemetics. Female and 2 antiemetics were risk factors for both delayed nausea (female-odds ratio [OR]: 1.918; 95% confidence interval [CI]: 1.292-2.848; p = 0.0012; 2 antiemetics-OR: 1.485; 95% CI: 1.000-2.204; p = 0.0498) and delayed vomiting (female-OR: 2.735; 95% CI: 1.410-5.304; p = 0.0029; 2 antiemetics-OR: 4.551; 95% CI: 2.116-9.785; p = 0.0001).

conclusionsIdentifying individual risk factors can facilitate personalized treatments for delayed CINV. We recommend a 3-antiemetic combination prophylaxis for CRC patients treated with L-OHP-based chemotherapy, especially for female patients.

Indexed as

AgedAntiemeticsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineClinical Trials, Phase III as TopicColorectal NeoplasmsDrug Therapy, CombinationFemaleFluorouracilHumansJapanLeucovorinMaleMiddle AgedNauseaNeurokinin-1 Receptor AntagonistsAntiemeticsCapecitabineFluorouracilLeucovorinNeurokinin-1 Receptor AntagonistsOrganoplatinum CompoundsOxaloacetatesAntiemeticsChemotherapyColorectal cancerNauseaOxaliplatinVomiting

Identifiers

PMID34656107
PMCPMC8520642
OpenAlexW3206964458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.